45 results
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
16 Jul 21
Other Events
4:31pm
believes are innovative and target scientifically validated pathways. These product candidates are designed to target tumor cells directly, modulate … the immune system. This discovery capability has enabled what Tempest believes is the rapid and efficient generation of a broad pipeline of innovative
424B3
TPST
Tempest Therapeutics Inc
11 May 21
Prospectus supplement
5:19pm
, or a combination of both, in each case that Tempest believes are innovative and target scientifically validated pathways. Tempest selected targets
8-K
2on y24inj
19 Dec 19
Geoff Nichol Appointed to Millendo Therapeutics Board of Directors
8:31am
DEFM14A
cgugiy59nk04z3vsjn
6 Nov 18
Proxy related to merger
12:00am
424B3
9ks6ixe v4xqt
5 Nov 18
Prospectus supplement
3:51pm
424B5
u6got7k6
8 Jan 15
Prospectus supplement for primary offering
12:00am
8-K
EX-99.2
08cp8yn
6 Jan 15
OvaScience Announces Proposed Public Offering of Common Stock
12:00am